Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Cells Blocked by PD-1 Antibody in NSCLC
NCT03282435Phase 1Unknown
- Sponsor
- Dalian University
- Start
- Jan 2018
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies, Cell Therapies
01
Overview
Phase 1, randomised trial of CIK cells + PD-1 inhibitor in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dalian University. Primary endpoints: progression-free survival at 5 years and metastasis-free survival at 5 years. Status: unknown.
02
Drugs
CIK cells + PD-1 inhibitor
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03282435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282435.